Moreover, aberrant p-tau aggregation has been reported in the epileptic human brain and in animal models of epilepsy (Machado et al., 2019; Liu et al., 2021; Canet et al., 2022), highlighting the role of pathological p-tau in the onset of epilepsy, suggesting that a therapy targeting the Pin1 binding site, especially p-tau, may also be a potential anti-epileptogenic therapy (Liu et al., 2016). The gene discussed is PIN1; the disease is epilepsy.